Michael Durante - Concepedia

Author

Michael Durante

University of Miami ORCID

Also Known As

Alexandra M. Poos, Durante, M., Frey, B., Helm, A., Hessel, P., Kim, E., Luft, S., M A Durante, M DURANTE, M. Durante

136

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

University of Miami Sylvester Comprehensive Cancer Center Moffitt Cancer Center Harvard University Memorial Sloan Kettering Cancer Center

About

Michael Durante is an author at University of Miami specializing in medicine, cell biology, and gene expression.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	424
2	Cell Biology	3	3	393
3	Engineering	1	1	31
4	Molecular Biology	1	1	31
5	Neuroscience	1	1	238

Michael Durante

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Single-cell analysis reveals new evolutionary complexity in uveal melanoma Michael Durante, Daniel A. Rodriguez, Stefan Kurtenbach, Nature Communications	2020	462
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma Holly Lee, Sungwoo Ahn, Ranjan Maity, Nature Medicine	2023	280
Single-cell analysis of olfactory neurogenesis and differentiation in adult humans Michael Durante, Stefan Kurtenbach, Zoukaa Sargi, Nature Neuroscience Olfactory NeurogenesisHuman CellDevelopmental BiologyNeuroanatomyCerebral Organoid	2020	238
Punctuated evolution of canonical genomic aberrations in uveal melanoma Matthew G. Field, Michael Durante, Hima Anbunathan, Nature Communications	2018	195
Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies Hui Yang, Stefan Kurtenbach, Ying Guo, Blood	2017	165
Cytoplasmic p27 promotes epithelial–mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation Dekuang Zhao, Alexander Besser, Seth A. Wander, Oncogene Stat3-mediated Twist1 UpregulationCancer BiologyTumor BiologyStat3 RescuesTranscriptional Regulation	2015	135
Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas Matthew G. Field, Michael Durante, Christina L. Decatur, Oncotarget	2016	121
Drug and disease signature integration identifies synergistic combinations in glioblastoma Vasileios Stathias, Anna M. Jermakowicz, Marie E. Maloof, Nature Communications	2018	108
Genomic Classification and Individualized Prognosis in Multiple Myeloma Francesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, Journal of Clinical Oncology	2024	95
HDAC Inhibition Enhances the <i>In Vivo</i> Efficacy of MEK Inhibitor Therapy in Uveal Melanoma Fernanda Faião‐Flores, Michael F. Emmons, Michael Durante, Clinical Cancer Research	2019	93

Page 1